In the latest trading session, 0.52 million Bioline Rx Ltd ADR (NASDAQ:BLRX) shares changed hands as the company’s beta touched 1.45. With the company’s most recent per share price at $0.43 changed hands at -$0.04 or -8.75% at last look, the market valuation stands at $34.38M. BLRX’s current price is a discount, trading about -348.84% off its 52-week high of $1.93. When we look at Bioline Rx Ltd ADR’s average trading volume, we note the 10-day average is 0.31 million shares, with the 3-month average coming to 277.38K.
Analysts gave the Bioline Rx Ltd ADR (BLRX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended BLRX as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Bioline Rx Ltd ADR’s EPS for the current quarter is expected to be -0.1.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Bioline Rx Ltd ADR (NASDAQ:BLRX) trade information
Instantly BLRX was in red as seen in intraday trades today. With action -1.78%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -72.62%, with the 5-day performance at -1.78% in the red. However, in the 30-day time frame, Bioline Rx Ltd ADR (NASDAQ:BLRX) is -33.14% down. Looking at the short shares, we see there were 0.14 million shares sold at short interest cover period of 0.93 days.
Bioline Rx Ltd ADR (BLRX) estimates and forecasts
Data shows that the Bioline Rx Ltd ADR share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -32.51% over the past 6 months, a 73.40% in annual growth rate that is considerably higher than the industry average of 17.50%. Year-over-year growth is forecast to reach 322.70% up from the last financial year.
Consensus estimates given by 3 financial analysts project the company’s revenue in the current quarter to hit an average of 4.12M. 3 analysts are of the opinion that Bioline Rx Ltd ADR’s revenue for the current quarter will be 4.74M. The estimates for the next quarter sales put growth at -1.20%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 21.53%. The 2024 estimates are for Bioline Rx Ltd ADR earnings to increase by 85.48%.
BLRX Dividends
Bioline Rx Ltd ADR is expected to release its next quarterly earnings report on 2024-Nov-04.
Bioline Rx Ltd ADR (NASDAQ:BLRX)’s Major holders
CVI HOLDINGS, LLC holds the second largest percentage of outstanding shares, with 1.126% or 0.82 million shares worth $0.46 million as of 2024-06-30.
With 39.99 shares estimated at $16681.0 under it, the former controlled 0.05% of total outstanding shares.
